Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May 13;53(9):3685-95.
doi: 10.1021/jm100057h.

Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models

Affiliations

Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models

Sunetra Ray et al. J Med Chem. .

Abstract

Among the known antimalarial drugs, chloroquine (CQ) and other 4-aminoquinolines have shown high potency and good bioavailability. Yet complications associated with drug resistance necessitate the discovery of effective new antimalarial agents. ADMET prediction studies were employed to evaluate a library of new molecules based on the 4-aminoquinolone-related structure of CQ. Extensive in vitro screening and in vivo pharmacokinetic studies in mice helped to identify two lead molecules, 18 and 4, with promising in vitro therapeutic efficacy, improved ADMET properties, low risk for drug-drug interactions, and desirable pharmacokinetic profiles. Both 18 and 4 are highly potent antimalarial compounds, with IC(50) values of 5.6 and 17.3 nM, respectively, against the W2 (CQ-resistant) strain of Plasmodium falciparum (for CQ, IC(50) = 382 nM). When tested in mice, these compounds were found to have biological half-lives and plasma exposure values similar to or higher than those of CQ; they are therefore desirable candidates to pursue in future clinical trials.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structures of 4-aminoquinolines compounds used to profile the ADMET properties for the series.
Figure 2
Figure 2
Relative percentages of metabolites for 8 (A) and 10 (B) identified by LC/MS after incubation with pooled human microsomes.
Figure 3
Figure 3
Inhibition of CYP2D6 enzyme activity by the test articles. Graph shows the amount of the metabolite 1′-OH-bufuralol produced in the presence of each test article (1 μM) as a percentage of control (no drug). Values <70% indicate significant inhibition.
Figure 4
Figure 4
Cytotoxic effects of the compounds on isolated rat hepatocytes. (a) MTT assay, (b) LDH assay
Figure 5
Figure 5
Plasma drug concentration in male CD-1 mice after a single oral dose at 50 mg/kg.
Scheme 1
Scheme 1
Synthesis of side chain substituted secondary amines. Reagents and Conditions: (a) RCHO (4 eq.), MeOH, 16 h.; (b) NaBH4 (4 eq.), MeOH, 2 h.

Similar articles

Cited by

References

    1. Kassel DB. Applications of high-throughput ADME in drug discovery. Curr Opin Chem Biol. 2004;8:339–345. - PubMed
    1. Shearer TW, Smith KS, Diaz D, Asher C, Ramirez J. The role of in vitro ADME assays in antimalarial drug discovery and development. Comb Chem High Throughput Screen. 2005;8:89–98. - PubMed
    1. WHO. World Malaria Report. World Health Organization; 2008.
    1. Madrid PB, Liou AP, DeRisi JL, Guy RK. Incorporation of an intramolecular hydrogen-bonding motif in the side chain of 4-aminoquinolines enhances activity against drug-resistant P. falciparum. J Med Chem. 2006;49:4535–4543. - PMC - PubMed
    1. Madrid PB, Sherrill J, Liou AP, Weisman JL, Derisi JL, Guy RK. Synthesis of ring-substituted 4-aminoquinolines and evaluation of their antimalarial activities. Bioorg Med Chem Lett. 2005;15:1015–1018. - PubMed

Publication types